Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1757-2215
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells ; volume:9 ; number:1 ; day:14 ; month:4 ; year:2016 ; pages:1-9 ; date:12.2016
Journal of ovarian research ; 9, Heft 1 (14.4.2016), 1-9, 12.2016
- Urheber
-
Abed, Mohammed Najim
- Beteiligte Personen und Organisationen
-
Abdullah, Marwan Ibrahim
Richardson, Alan
SpringerLink (Online service)
- DOI
-
10.1186/s13048-016-0234-y
- URN
-
urn:nbn:de:1111-2016041619543
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Abed, Mohammed Najim
- Abdullah, Marwan Ibrahim
- Richardson, Alan
- SpringerLink (Online service)
Ähnliche Objekte (12)
BH3-mimetics: recent developments in cancer therapy
BH3 mimetics for the treatment of prostate cancer
A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells
BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
Evaluation of BH3 mimetics as a novel therapeutic strategy in acute myeloid leukemia
BH3-mimetics: recent developments in cancer therapy
BH3 mimetics for the treatment of prostate cancer
A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells
BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
Evaluation of BH3 mimetics as a novel therapeutic strategy in acute myeloid leukemia
BH3-mimetics: recent developments in cancer therapy
BH3 mimetics for the treatment of prostate cancer
A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells
BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy